WO1999050662A3 - Method of measuring bone resorption rate - Google Patents

Method of measuring bone resorption rate Download PDF

Info

Publication number
WO1999050662A3
WO1999050662A3 PCT/FI1999/000262 FI9900262W WO9950662A3 WO 1999050662 A3 WO1999050662 A3 WO 1999050662A3 FI 9900262 W FI9900262 W FI 9900262W WO 9950662 A3 WO9950662 A3 WO 9950662A3
Authority
WO
WIPO (PCT)
Prior art keywords
trap
bone resorption
resorption rate
methods
measuring bone
Prior art date
Application number
PCT/FI1999/000262
Other languages
French (fr)
Other versions
WO1999050662A2 (en
Inventor
Jussi Halleen
Kalervo Vaeaenaenen
Original Assignee
Jussi Halleen
Kalervo Vaeaenaenen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jussi Halleen, Kalervo Vaeaenaenen filed Critical Jussi Halleen
Priority to AT99913329T priority Critical patent/ATE279728T1/en
Priority to EP99913329A priority patent/EP1068533B1/en
Priority to AU31491/99A priority patent/AU748663B2/en
Priority to JP2000541520A priority patent/JP3523200B2/en
Priority to DE69921107T priority patent/DE69921107T2/en
Publication of WO1999050662A2 publication Critical patent/WO1999050662A2/en
Publication of WO1999050662A3 publication Critical patent/WO1999050662A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/42—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving phosphatase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/916—Hydrolases (3) acting on ester bonds (3.1), e.g. phosphatases (3.1.3), phospholipases C or phospholipases D (3.1.4)

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Apparatus For Radiation Diagnosis (AREA)
  • Analysing Materials By The Use Of Radiation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analyzing Materials By The Use Of Ultrasonic Waves (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Glass Compositions (AREA)
  • Steroid Compounds (AREA)
  • Luminescent Compositions (AREA)

Abstract

Tartrate-resistant acid phosphatase (TRAP) has been used as a marker from bone resorption. However, there are two forms of said enzyme in the body: TRAP 5a and TRAP 5b, of which TRAP 5b is a much more specific marker. The present invention is directed to an immunoassay for measuring the bone resorption rate, which methods enables the specific determination of TRAP 5b, whereby the amount of TRAP 5b reflects the bone resorption rate. The method is useful in diagnosing disorders associated with a change in the bone resorption rate, such as osteoporosis. Methods of screening for susceptibility to such disorders, and method of monitoring the effect of treatment are also provided. Further a test-kit useful in said methods is provided.
PCT/FI1999/000262 1998-04-01 1999-03-30 Method of measuring bone resorption rate WO1999050662A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
AT99913329T ATE279728T1 (en) 1998-04-01 1999-03-30 METHOD FOR MEASURING BONE RESORPTION RATE
EP99913329A EP1068533B1 (en) 1998-04-01 1999-03-30 Method of measuring bone resorption rate
AU31491/99A AU748663B2 (en) 1998-04-01 1999-03-30 Method of measuring bone resorption rate
JP2000541520A JP3523200B2 (en) 1998-04-01 1999-03-30 How to measure bone resorption rate
DE69921107T DE69921107T2 (en) 1998-04-01 1999-03-30 METHOD FOR MEASURING THE BONE RESORPTION RATE

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FI980748A FI980748A (en) 1998-04-01 1998-04-01 Method for determining the rate of resorption in bone
FI980748 1998-04-01

Publications (2)

Publication Number Publication Date
WO1999050662A2 WO1999050662A2 (en) 1999-10-07
WO1999050662A3 true WO1999050662A3 (en) 1999-11-18

Family

ID=8551441

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FI1999/000262 WO1999050662A2 (en) 1998-04-01 1999-03-30 Method of measuring bone resorption rate

Country Status (12)

Country Link
EP (1) EP1068533B1 (en)
JP (1) JP3523200B2 (en)
CN (1) CN1145030C (en)
AT (1) ATE279728T1 (en)
AU (1) AU748663B2 (en)
CZ (1) CZ296736B6 (en)
DE (1) DE69921107T2 (en)
DK (1) DK1068533T3 (en)
ES (1) ES2232124T3 (en)
FI (1) FI980748A (en)
PT (1) PT1068533E (en)
WO (1) WO1999050662A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7074903B2 (en) 2002-04-30 2006-07-11 Nitto Boseki Co., Ltd. Monoclonal antibody specific to tartrate-resistant acid phosphatase 5b and use thereof
JP4483780B2 (en) 2003-02-25 2010-06-16 日東紡績株式会社 Immunoassay for tartrate-resistant acid phosphatase 5b and kit used therefor
WO2008081922A1 (en) 2006-12-28 2008-07-10 Nitto Boseki Co., Ltd METHOD FOR PRODUCTION OF TRACP5b
GB0806801D0 (en) * 2008-04-15 2008-05-14 Immunodiagnostic Systems Ltd Substrate
CN107002065B (en) * 2014-08-22 2019-04-26 日东纺绩株式会社 To TRACP-5b(tartaric acid repellence acid phosphatase 5b) there is specific albuminimetry
CN113533742A (en) * 2021-07-16 2021-10-22 河北农业大学 Method for determining IgG absorption efficiency of newborn lambs

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08262019A (en) * 1995-03-20 1996-10-11 Hoechst Japan Ltd Diagnostic agent of osteoporosis

Non-Patent Citations (12)

* Cited by examiner, † Cited by third party
Title
CHEMICAL ABSTRACTS, vol. 117, no. 5, 3 August 1992, Columbus, Ohio, US; abstract no. 41370y, ALAM, A.S.M.T. ET AL.: "Endothelin inhibits osteoclastic bone resorption by a direct effect on cell motility: implications for the vascular control of bone resorption" page 202; column 2; XP002900534 *
CHEMICAL ABSTRACTS, vol. 123, no. 21, 20 November 1995, Columbus, Ohio, US; abstract no. 282976e, CHAMBERLAIN, P. ET AL.: "Generation and characterization of monoclonal antibodies to human type-5 tartrate-resistant acid phosphatase: development of a specific immunoassay of the isoenzyme in serum" page 917; column 1; XP002900531 *
CHEMICAL ABSTRACTS, vol. 126, no. 3, 20 January 1997, Columbus, Ohio, US; abstract no. 29683f, FUKUOKA, H.: "Tartrate-resistant acid phorphatase as a resorption marker of bone" page 402; column 2; XP002900535 *
CHEMICAL ABSTRACTS, vol. 127, no. 3, 21 July 1997, Columbus, Ohio, US; abstract no. 32591a, JANCKILA, A.J. ET AL.: "Characterization of monoclonal antibodies specific to human tartrate-resistant acid phosphatase" page 491; column 1; XP002900532 *
CHEMICAL ABSTRACTS, vol. 128, no. 23, 8 June 1998, Columbus, Ohio, US; abstract no. 280012s, NAKANISHI, M. ET AL.: "Improved method for measuring tartrate-resistant acid phosphatase activity in serum" page 189; column 1; XP002900536 *
CHEMICAL ABSTRACTS, vol. 129, no. 6, 10 August 1998, Columbus, Ohio, US; abstract no. 64633y, HALLEEN, J.M. ET AL.: "Characterization of serum tartrate-resistant acid phosphatase and development of a direct two-site immunoassay" page 304; column 2; XP002900533 *
CLIN CHEM., vol. 41, no. 10, 1995, WASHINGTON, D.C., pages 1495 - 1499 *
CLIN. CHEM., vol. 44, no. 2, 1998, WASHINGTON, D.C., pages 221 - 225 *
ENDOCRINOLOGY, vol. 130, no. 6, 1992, BALTIMORE, pages 3617 - 3724 *
HORUMON TO RINSHO, vol. 44, no. 11, 1996, pages 1145 - 1149 *
HYBRIDOMA, vol. 16, no. 2, 1997, pages 175 - 182 *
J. BONE MINER. RES., vol. 13, no. 4, 1998, pages 683 - 687 *

Also Published As

Publication number Publication date
FI980748A (en) 1999-10-02
CZ20003578A3 (en) 2001-03-14
AU3149199A (en) 1999-10-18
CZ296736B6 (en) 2006-06-14
ES2232124T3 (en) 2005-05-16
DE69921107D1 (en) 2004-11-18
DK1068533T3 (en) 2005-02-14
ATE279728T1 (en) 2004-10-15
JP3523200B2 (en) 2004-04-26
DE69921107T2 (en) 2005-07-28
WO1999050662A2 (en) 1999-10-07
AU748663B2 (en) 2002-06-06
CN1145030C (en) 2004-04-07
FI980748A0 (en) 1998-04-01
CN1295667A (en) 2001-05-16
JP2002510050A (en) 2002-04-02
EP1068533B1 (en) 2004-10-13
PT1068533E (en) 2005-02-28
EP1068533A2 (en) 2001-01-17

Similar Documents

Publication Publication Date Title
AU2560599A (en) Diagnosis and treatment of aur1 and/or aur2 related disorders
WO2002085285A3 (en) Methods and reagents for regulating bone and cartilage formation
CA2239692A1 (en) Diagnosis and treatment of aur-1 and/or aur-2 related disorders
WO2000018899A3 (en) Angiotensin converting enzyme homolog and its use
WO2001039694A3 (en) Repair of damaged tissue
WO1996018738A3 (en) PROBIN TYROSINE KINASE (PYK2) ITS cDNA CLONING AND ITS USES
EP0911321A3 (en) Compounds for the treatment of osteoporosis
WO1998058911A3 (en) Prostaglandin agonists
EP1336936A3 (en) Method and system for diagnosis of plant
WO2000018954A3 (en) Use of pex in the treatment of metabolic bone diseases
CA2119761A1 (en) Method for the Diagnosis of Blood Coagulation Disorders
DE69610558D1 (en) Test für thrombosegefahr
WO1999050662A3 (en) Method of measuring bone resorption rate
WO2001057537A3 (en) Methods for diagnosis of alzheimer's disease
CA2271544A1 (en) Method to detect bone and other connective tissue disorders in humans and animals
GB9718358D0 (en) Chemical modification
ATE332397T1 (en) METHOD FOR QUALITY CONTROL IN THE CONSTRUCTION OF OLIGOME GRIDS
DE69621837D1 (en) METHODS FOR DETECTING ALZHEIMERSCH DISEASE
WO1998049317A3 (en) Diagnosis and treatment of phosphatase- 0r kinase-related disorders
WO1999041387A3 (en) Prostate-associated serine protease
EP1039394A3 (en) Method and apparatus for analyzing data
DE69734890D1 (en) RdgB PROTEINS
CA2105606A1 (en) Method for the determination of lupus anticoagulant antibodies that cause thrombosis
WO2002058323A3 (en) Method for identifying modulators of bace
WO2005060627A3 (en) Methods of assessing the risk of non-traumatic bone fracture

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 99804628.0

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AT AU AZ BA BB BG BR BY CA CH CN CU CZ CZ DE DE DK DK EE EE ES FI FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AT AU AZ BA BB BG BR BY CA CH CN CU CZ CZ DE DE DK DK EE EE ES FI FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 31491/99

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1999913329

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: PV2000-3578

Country of ref document: CZ

NENP Non-entry into the national phase

Ref country code: KR

WWP Wipo information: published in national office

Ref document number: 1999913329

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: PV2000-3578

Country of ref document: CZ

NENP Non-entry into the national phase

Ref country code: CA

WWG Wipo information: grant in national office

Ref document number: 31491/99

Country of ref document: AU

WWG Wipo information: grant in national office

Ref document number: 1999913329

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: PV2000-3578

Country of ref document: CZ